Orion and Mylan settle patent dispute over the proprietary drug Stalevo®
(Thomson Reuters ONE) -
ORION CORPORATION STOCK EXCHANGE RELEASE 25 JULY 2013 at 11.25 a.m. EEST
Orion Corporation ("Orion") and Mylan Pharmaceuticals Inc. ("Mylan") have
executed a settlement and license agreement to settle the lawsuit filed by Orion
in the United States against Mylan regarding Mylan's submission of an
abbreviated new drug application ("ANDA") for generic versions of Orion's
Stalevo® (carbidopa/levodopa/entacapone) product.
The lawsuit was filed by Orion in the U.S. in April 2012. Under the terms of the
settlement and license agreement, Mylan shall be authorized to launch generic
versions of the Stalevo product (strengths 12.5/50/200 mg; 18.75/75/200 mg;
25/100/200 mg; 31.25/125/200 mg; 37.5/150/200 mg and 50/200/200 mg) immediately
after entry of the agreement.
Subject to the Court's approval, the lawsuit against Mylan will be dismissed and
the U.S. Patents Nos. 5,446,194, 6,500,867 and 6,797,732 shall remain in force.
In compliance with the applicable U.S. laws, Orion will file the above agreement
with the United States Federal Trade Commission and the United States Department
of Justice.
Orion Corporation
Timo Lappalainen Olli Huotari
President and CEO SVP, Corporate Functions
Contact person:
Olli Huotari, SVP, Corporate Functions
tel. +358 10 426 3054
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via Thomson Reuters ONE
[HUG#1717831]
Unternehmensinformation / Kurzprofil:
Datum: 25.07.2013 - 10:26 Uhr
Sprache: Deutsch
News-ID 281670
Anzahl Zeichen: 2906
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion and Mylan settle patent dispute over the proprietary drug Stalevo®"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
